FDA优先审查-话题@MedSci

[GetTopicListResponse(id=2054959, encodeId=c49b20549598a, content=<a href='/topic/show?id=4e25e29816' target=_blank style='color:#2F92EE;'>#FDA优先审查#</a>, objectTitle=阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查, objectType=article, longId=202339, objectId=864620233978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864620233978, replyNumber=0, likeNumber=56, createdTime=2021-02-14, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864620233978, moduleTitle=阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864620233978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2054958, encodeId=cc3720549580d, content=<a href='/topic/show?id=4e25e29816' target=_blank style='color:#2F92EE;'>#FDA优先审查#</a>, objectTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, objectType=article, longId=185842, objectId=eae01858423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae01858423e, replyNumber=0, likeNumber=37, createdTime=2020-09-14, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae01858423e, moduleTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae01858423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2054957, encodeId=7120205495e08, content=<a href='/topic/show?id=4e25e29816' target=_blank style='color:#2F92EE;'>#FDA优先审查#</a>, objectTitle=Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查, objectType=article, longId=165296, objectId=373b1652964b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=373b1652964b, replyNumber=0, likeNumber=33, createdTime=2020-02-09, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=373b1652964b, moduleTitle=Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=373b1652964b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2054956, encodeId=e179205495658, content=<a href='/topic/show?id=4e25e29816' target=_blank style='color:#2F92EE;'>#FDA优先审查#</a>, objectTitle=安斯泰来的AML药物获FDA优先审查, objectType=article, longId=139544, objectId=c604139544d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c604139544d4, replyNumber=0, likeNumber=37, createdTime=2018-06-25, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c604139544d4, moduleTitle=安斯泰来的AML药物获FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c604139544d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2054955, encodeId=401620549553a, content=<a href='/topic/show?id=4e25e29816' target=_blank style='color:#2F92EE;'>#FDA优先审查#</a>, objectTitle=吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格，将极大简化丙肝临床治疗, objectType=article, longId=61804, objectId=93ed618041a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93ed618041a, replyNumber=0, likeNumber=41, createdTime=2016-04-15, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93ed618041a, moduleTitle=吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格，将极大简化丙肝临床治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93ed618041a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2054954, encodeId=66ce205495428, content=<a href='/topic/show?id=4e25e29816' target=_blank style='color:#2F92EE;'>#FDA优先审查#</a>, objectTitle=FDA优先审查利伐沙班和阿哌沙班新适应证, objectType=article, longId=4295, objectId=ced84295fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced84295fb, replyNumber=0, likeNumber=43, createdTime=2013-01-29, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced84295fb, moduleTitle=FDA优先审查利伐沙班和阿哌沙班新适应证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced84295fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA优先审查

2020-05-29

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#FDA优先审查#

阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查

2021-02-14

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#FDA优先审查#

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查

2020-09-14

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#FDA优先审查#

Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查

2020-02-09

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#FDA优先审查#

安斯泰来的AML药物获FDA优先审查

2018-06-25

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#FDA优先审查#

吉利德泛基因型丙肝鸡尾酒疗法SOF/VEL获FDA优先审查资格，将极大简化丙肝临床治疗

2016-04-15

仁医06 (审核中...)

前往app查看评论内容

#FDA优先审查#

FDA优先审查利伐沙班和阿哌沙班新适应证

2013-01-29

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#FDA优先审查#

科室

工具

服务